Jentadueto

Metformin hydrochloride and linagliptin, the active ingredient in Jentadueto, is a biguanide/DPP‑4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving insulin sensitivity and enhancing incretin‑mediated insulin secretion.

GNH USA supplies Jentadueto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jentadueto is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder requiring glycaemic control.

- Type 2 diabetes mellitus: improves overall glycaemic control when used with diet and exercise. - Inadequate control on metformin alone: adds DPP‑4 inhibition to further lower blood glucose. - Combination therapy with other antidiabetics: provides complementary mechanisms to achieve target HbA1c levels.

Jentadueto may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhoea: increased bowel movements. - Headache: occasional tension‑type headache. - Upper respiratory tract infection: symptoms of cold or sinusitis. - Abdominal discomfort: general stomach pain. - Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: inflammation of the pancreas. - Hepatic dysfunction: abnormal liver enzyme elevations. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Acute renal failure: sudden loss of kidney function.

Before prescribing Jentadueto, clinicians should evaluate patient‑specific risk factors and monitor relevant clinical parameters.

- Renal function: assess eGFR before initiation and periodically thereafter. - Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment. - Hypoglycaemia: monitor closely if used with insulin or sulfonylureas. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Vitamin B12 deficiency: consider periodic monitoring during long‑term therapy. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Jentadueto can interact with several medicines, requiring dose adjustments or monitoring.

Major Interactions (Avoid): - Cimetidine: may increase metformin plasma concentrations. - Iodinated contrast agents: can precipitate acute renal failure when combined with metformin. - Alcohol excess: raises risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Sulfonylureas: heightened risk of hypoglycaemia. - Thiazolidinediones: additive glucose‑lowering effect. - Diuretics: may affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and electrolytes.